DIFI_Cetuximab_Resistance_ENU_Mutagenesis. DIFI_Cetuximab_Resistance_ENU_Mutagenesis

Cetuximab is a targeted monoclonal antibody against the epidermal growth factor receptor (EGFR) which is used therapeutically for the treatment of KRAS wild-type colorectal cancer (CRC). The Cetuximab sensitive KRAS wild-type CRC cell line DIFI has been treated with a fixed concentration of ENU for 24 hours and then selected with Cetuximab until drug resistant clones emerged. These clones have been pooled and will have genes causally implicated in cancer sequenced to identify common point mutations in multiple independently derived drug resistant clones as a forward genetic screen for mechanisms of resistance to Cetuximab in CRC.